<DOC>
	<DOCNO>NCT00365287</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy radiation therapy donor umbilical cord blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell exactly match patient 's blood . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect give combination chemotherapy together total-body irradiation donor umbilical cord blood transplant see well work treat patient advanced hematologic cancer , metastatic breast cancer , kidney cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant Treating Patients With Advanced Hematologic Cancer , Metastatic Breast Cancer , Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety nonmyeloablative preparative regimen comprise cyclophosphamide , fludarabine , total-body irradiation without anti-thymocyte globulin , term non-relapse mortality day 100 post-transplantation , patient advance hematologic malignancy , metastatic breast cancer , renal cell cancer undergo umbilical cord blood transplantation unrelated donor . Secondary - Determine hematopoietic recovery degree chimerism day 21 , 60 , 100 , 180 , 360 post-transplantation . - Determine incidence grade II-IV III-IV acute graft-versus-host disease ( GVHD ) day 100 post-transplantation chronic GVHD 1 year post-transplantation . - Evaluate risk relapse 1 year post-transplantation . - Determine overall survival 1 year post-transplantation . OUTLINE : - Nonmyeloablative preparative regimen : Patients receive cyclophosphamide IV 2 hour day -6 fludarabine IV 1 hour day -6 -2 . Patients also undergo total-body irradiation day -1 . Some patients* may also receive anti-thymocyte globulin ( ATG ) IV twice daily day -6 -4 . NOTE : *Patients prior combination chemotherapy within past 3 month OR receive 1 prior induction course treatment acute lymphoblastic leukemia , acute myeloid leukemia , myelodysplastic syndrome , chronic myelogenous leukemia blast crisis receive ATG preparative regimen . - Umbilical cord blood transplantation ( UCBT ) : Patients undergo UCBT unrelated donor day 0 . - Graft-versus-host disease prophylaxis : Patients receive cyclosporine IV 2 hour orally 2-3 time daily begin day -3 continue day 100 follow taper day 180 . Patients also receive mycophenolate mofetil IV orally twice daily begin day -3 continue day 30 7 day engraftment . After transplantation , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia ( AML ) , meet 1 follow criterion : In first complete remission ( CR1 ) morphology AND high risk , evidence 1 following : AML secondary myelodysplastic syndrome ( MDS ) Highrisk cytogenetics , associate MDS complex karyotype More 2 course therap require obtain CR In second great CR morphology In morphologic relapse persistent disease , define &gt; 5 % blast normocellular bone marrow OR percentage blast blast unique morphologic marker ( e.g. , auer rod ) In cytogenetic relapse ( without morphologic relapse ) Acute lymphoblastic leukemia ( ALL ) , meet 1 follow criterion : In CR1 morphology AND high risk , evidence 1 following : Highrisk cytogenetics , ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) , MLL rearrangements More 1 course therapy require obtain CR In second great CR morphology In morphologic relapse persistent disease define AML In cytogenetic relapse ( without morphologic relapse ) Chronic myelogenous leukemia All type allow except refractory blast crisis NonHodgkin 's lymphoma ( NHL ) No intermediate highgrade NHL mantle cell NHL progressive salvage therapy Stable disease allow provide nonbulky Hodgkin 's lymphoma No progressive disease salvage therapy Stable disease allow provide nonbulky Chronic lymphocytic leukemia Multiple myeloma MDS Any subtype allow , include refractory anemia severe pancytopenia complex cytogenetics Less 5 % blast If patient blast ≥ 5 % must undergo induction therapy transplantation Metastatic breast cancer Disease must respond recent chemotherapy OR plateau response chemotherapy Renal cell cancer Acquired bone marrow failure syndromes Small percentage blast equivocal marrow regeneration v early relapse allow provide associate cytogenetic marker consistent relapse ( patient AML ALL ) Must 4/6 HLAA , B , DRB1 match unrelated umbilical cord blood donor available No 5/6 6/6 HLAA , B , DRB1 match sibling donor available No 2 antigen mismatch HLAA , B , DRB1 loci NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % OR Lansky performance status 50100 % ( pediatric patient ) Albumin &gt; 2.5 g/dL Creatinine ≤ 2.0 mg/dL ( adult ) OR creatinine clearance &gt; 40 mL/min ( pediatric patient ) Adults creatinine &gt; 1.2 mg/dL history renal dysfunction must creatinine clearance &gt; 40 mL/min Transaminases &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 3 time ULN LVEF ≥ 35 % DLCO &gt; 30 % predict Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence HIV infection know HIVpositivity No decompensated congestive heart failure No uncontrolled cardiac arrhythmia No requirement supplemental oxygen No active , serious infection Recent mold infection ( e.g. , Aspergillus ) allow provided patient receive ≥ 30 day appropriate treatment AND infection control clear infectious disease specialist PRIOR CONCURRENT THERAPY : No prior irradiation precludes safe administration 1 additional dose 200 cGy totalbody irradiation At least 3 month since prior myeloablative bone marrow transplantation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>